Budenofalk治疗哮喘疗效如何？

How effective is it in treating asthma? The MIST trial enrolled children with modified API positivity, recurrent wheezing, and ≥1 exacerbation in the past year but with low severity (defined as infrequent albuterol use and infrequent nocturnal awakenings between exacerbations). All subjects first received pretreatment with nightly placebo doses of Budenofalk inhalation suspension for 2 weeks (run-in period) and albuterol if necessary, and then received 52 weeks (treatment period) of randomized treatment. The intermittent treatment group (n=139) received 1 mg Budenofalk inhalation suspension twice a day for 7 days after the respiratory disease was diagnosed; the daily treatment group (n=139) received 0.5 mg budesonide inhalation suspension every night. Each group was also given a corresponding placebo dose of the drug.

The results showed that the incidence rates of asthma exacerbation in the Budenofalk treatment group and the intermittent treatment group were 0.97/(patient·year) and 0.95/(patient·year) respectively, and the relative incidence rate in the intermittent treatment group was 0.99. The incidence rates of non-serious adverse events and serious adverse events were also similar between the two groups, but the average cumulative exposure of Budenofalk in the intermittent treatment group was significantly smaller than that in the daily treatment group (45.7 mg vs 149.9 mg).

First developed and marketed by AstraZeneca Pharmaceuticals in 1981, it is a non-halogenated glucocorticoid that has a strong local anti-inflammatory effect and can inhibit early bronchospasm and late allergic reactions. It is one of the important drugs for the treatment of allergic asthma. Currently, Budenofalk has not been launched in China. Medical Travel has learned that the price of a box of 100 tablets of Budenofalk sold abroad is around $800. Since the exchange rate fluctuates and the price is not fixed, please consult the medical companion passenger service for specific prices.